Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546302 | 0.85 | POLB (0.47) | POLBJAK2JAK1JAK3 | |
| SCHEMBL17546299 | 0.82 | POLB (0.44) | POLB | |
| SCHEMBL19014557 | 0.80 | POLB (0.56) | POLB | |
| SCHEMBL24158934 | 0.79 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL30778397 | 0.79 | POLB (0.48) | POLBHDAC2 | |
| SCHEMBL19249275 | 0.79 | DPP4 (0.46) | JAK2JAK1JAK3 | |
| SCHEMBL24568323 | 0.76 | DPP4 (0.36) | JAK2JAK1JAK3 | |
| SCHEMBL8141531 | 0.76 | — | — | |
| SCHEMBL17546300 | 0.75 | POLB (0.43) | POLBMCL1JAK2JAK1JAK3 | |
| SCHEMBL12521943 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | POLB 4110/4885HSD11B1 52/4885HDAC2 191/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | POLB 4110/4885HSD11B1 52/4885HDAC2 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.